AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38145715 — intervention group
Group type: COMPARATOR
Intervention: Unsupported dCBT intervention (SilverCloud)
Number of subjects: 426
Study 38145715 — intervention group
Group type: COMPARATOR
Intervention: Provider-level outreach (using a clinic patient registry)
Number of subjects: 426
Study 38145715 — intervention group
Group type: COMPARATOR
Intervention: Inreach (traditional provider referral)
Number of subjects: 426
Study 38145791 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated PFT survivors
Number of subjects: 35
Study 38145791 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-irradiated PFT survivors
Number of subjects: 35
Study 38145791 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study 38146133 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysubstance use patterns; specific intervention details not available
Number of subjects: 0
Study 38146234 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive auricular vagus nerve stimulation (AVNS)
Number of subjects: 0
Study 38146234 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular vagus nerve stimulation
Number of subjects: 0
Study 38146256 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anti-coagulants (OAC)
Number of subjects: 52530
Study 38146256 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC
Number of subjects: 52530
Study 38146256 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital rhythm control strategies (catheter ablation)
Number of subjects: 52530
Study 38146256 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital rhythm control strategies (electronic cardioversion)
Number of subjects: 52530
Study 38146256 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital rhythm control strategies (anti-arrhythmic drug use)
Number of subjects: 52530
Study 38146531 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study 38146531 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 0
Study 38146651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study 38146651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38146908 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin continuation within 5 days before surgery (n=269)
Number of subjects: 474
Study 38146908 — intervention group
Group type: COMPARATOR
Intervention: Non-aspirin group (stopped aspirin no later than 5 days before surgery) (n=205)
Number of subjects: 474
Study 38147031 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered HIV self-testing (HIVST)
Number of subjects: 55
Study 38147031 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered PrEP
Number of subjects: 55
Study 38147031 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling for STI testing
Number of subjects: 55
Study 38147031 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer psychosocial support
Number of subjects: 55
Study 38147107 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-parent families
Number of subjects: 2828
Study 38147107 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepfamilies
Number of subjects: 2828
Study 38147107 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepfamilies (3-10 years)
Number of subjects: 2828
Study 38147107 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepfamilies (11-17 years)
Number of subjects: 2828
Study 38147107 — intervention group
Group type: COMPARATOR
Intervention: Traditional families
Number of subjects: 2828
Study 38147137 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab 10 mg/kg weekly for 4 weeks then every 2 weeks for 8 weeks
Number of subjects: 23
Study 38147153 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin-based transarterial chemoembolization (IDA-TACE)
Number of subjects: 128
Study 38147153 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin-based transarterial chemoembolization (DOX-TACE)
Number of subjects: 128
Study 38147153 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA-TACE
Number of subjects: 128
Study 38147153 — intervention group
Group type: COMPARATOR
Intervention: DOX-TACE
Number of subjects: 128
Study 38147180 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical reconstructive therapy with adjunctive use of Er:YAG laser
Number of subjects: 24
Study 38147180 — intervention group
Group type: COMPARATOR
Intervention: Surgical reconstructive therapy without adjunctive use of Er:YAG laser (control group)
Number of subjects: 24
Study 38147180 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (laser and control)
Number of subjects: 24
Study 38147180 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical reconstructive therapy
Number of subjects: 24
Study 38147268 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive pulsed radiofrequency (NipRF) therapy applied to the greater occipital nerve (GON)
Number of subjects: 0
Study 38147268 — intervention group
Group type: COMPARATOR
Intervention: Greater occipital nerve (GON) block under ultrasound guidance
Number of subjects: 0
Study 38147281 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-whey-protein microspheres (14 mg daily, 25 mg daily, 50 mg daily) for 12 weeks
Number of subjects: 59
Study 38147281 — intervention group
Group type: COMPARATOR
Intervention: Prior oral iron product
Number of subjects: 59
Study 38147326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive food-as-medicine program (providing healthy groceries for 10 meals per week, dietitian consultations, nurse evaluations, health coaching, and diabetes education for 1 year)
Number of subjects: 465
Study 38147326 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 465
Study 38147326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive food-as-medicine program
Number of subjects: 465
Study 38147413 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA haplotype A*02:01-B*15:01-C*03:04-DRB1*04:01-DQB1*03:02
Number of subjects: 131
Study 38147413 — intervention group
Group type: COMPARATOR
Intervention: Neuropathy without pain (control group)
Number of subjects: 131
Study 38147491 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 0
Study 38147491 — intervention group
Group type: COMPARATOR
Intervention: Neutral scripts
Number of subjects: 0
Study 38147525 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG3312 (Pan-SIK Inhibitor)
Number of subjects: 0
Study 38147711 — intervention group
Group type: EXPERIMENTAL
Intervention: Written document and verbal information
Number of subjects: 60
Study 38147711 — intervention group
Group type: COMPARATOR
Intervention: Verbal information only
Number of subjects: 60
Study 38147816 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab biosimilar (HLX02), pertuzumab, and chemotherapy
Number of subjects: 45
Study 38147871 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB + RPV (Q8W)
Number of subjects: 41
Study 38147871 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB + RPV (Q4W)
Number of subjects: 41
Study 38147871 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB + RPV
Number of subjects: 41
Study 38148064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin 0.2 IU/ml
Number of subjects: 39
Study 38148064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin 0.1 IU/ml
Number of subjects: 39
Study 38148064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin 0.05 IU/ml
Number of subjects: 39
Study 38148064 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 39
Study 38148327 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT200 combined with SCT-I10A
Number of subjects: 21
Study 38148327 — intervention group
Group type: COMPARATOR
Intervention: SCT200 monotherapy (from previous phase I study)
Number of subjects: 21
Study 38148411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-based regimens
Number of subjects: 170
Study 38148411 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab-based regimens
Number of subjects: 170
Study 38148411 — intervention group
Group type: COMPARATOR
Intervention: Other chemotherapy regimens
Number of subjects: 170
Study 38148468 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (20 μg) for 15 minutes after internal mammary artery harvesting
Number of subjects: 100
Study 38148468 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation for 15 minutes after internal mammary artery harvesting
Number of subjects: 100
Study 38148664 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel of 20 metabolites including lactate, cotinine, salicylate, 6 phosphatidylcholines, and 4 sphingomyelins.
Number of subjects: 61
Study 38148664 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lactate, arginine, and proline metabolism.
Number of subjects: 61
Study 38148664 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 61
Study 38148846 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/wk of moderate-intensity aerobic exercise (low-dose)
Number of subjects: 39
Study 38148846 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 min/wk of moderate-intensity aerobic exercise (high-dose)
Number of subjects: 39
Study 38148846 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 39
Study 38149026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 19
Study 38149073 — intervention group
Group type: EXPERIMENTAL
Intervention: Kombucha enriched with inulin (2.53 g/220 mL) and vitamins (B1 - 0.59 mg, B2 - 0.55 mg, B3 - 5.9 mg, B6 - 0.7 mg, folic acid - 81.4 μg/220 mL)
Number of subjects: 40
Study 38149073 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 40
Study 38149099 — intervention group
Group type: EXPERIMENTAL
Intervention: PyroH plus chemotherapy
Number of subjects: 333
Study 38149099 — intervention group
Group type: COMPARATOR
Intervention: HP plus chemotherapy
Number of subjects: 333
Study 38149261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lived experience of seeking help for their own mental health conditions
Number of subjects: 4245
Study 38149261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lived experience of receiving medical treatment for a mental illness
Number of subjects: 4245
Study 38149261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lived experience of having a friend or family member affected by mental illness
Number of subjects: 4245
Study 38149261 — intervention group
Group type: EXPERIMENTAL
Intervention: Being surrounded by colleagues who are less stigmatising
Number of subjects: 4245
Study 38149261 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing psychotherapy to patients
Number of subjects: 4245
Study 38149261 — intervention group
Group type: EXPERIMENTAL
Intervention: Being open to case discussion, supervision, or Balint groups
Number of subjects: 4245
Study 38149261 — intervention group
Group type: EXPERIMENTAL
Intervention: Actively participating in case discussion, supervision, or Balint groups
Number of subjects: 4245
Study 38149403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fosphenytoin 18 mg/kg (high dose)
Number of subjects: 17
Study 38149403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fosphenytoin 12 mg/kg (low dose)
Number of subjects: 17
Study 38149403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 38149413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy kefir
Number of subjects: 70
Study 38149413 — intervention group
Group type: COMPARATOR
Intervention: Placebo dairy drink
Number of subjects: 70
Study 38149620 — intervention group
Group type: EXPERIMENTAL
Intervention: Microembolic signals (MES) detected using transcranial Doppler within 24 hours post-stroke.
Number of subjects: 61
Study 38149620 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 61
Study 38149636 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 51
Study 38149948 — intervention group
Group type: EXPERIMENTAL
Intervention: CD30.CAR-T therapy
Number of subjects: 26
Study 38150009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (900 mg/day)
Number of subjects: 11
Study 38150126 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model based on AU17 (chin raising) and AU20 (lip stretching)
Number of subjects: 155
Study 38150126 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model based on all AUs
Number of subjects: 155
Study 38150126 — intervention group
Group type: EXPERIMENTAL
Intervention: Merged ML model utilizing gaze, eye landmarks, head position, and facial landmarks
Number of subjects: 155
Study 38150126 — intervention group
Group type: COMPARATOR
Intervention: AUs known to be associated with pain in awake patients
Number of subjects: 155
Study 38150232 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication for opioid use disorder (MOUD) treatment offered at intake, throughout incarceration, and upon release.
Number of subjects: 0
Study 38150232 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of requirements into medical provider contracts to screen all people entering jails for OUD.
Number of subjects: 0
Study 38150232 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample contractual language for medical provider proposals to integrate MOUD treatment.
Number of subjects: 0
Study 38150256 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1.62% testosterone gel
Number of subjects: 5204
Study 38150256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5204
Study 38150260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity care with higher doses of GDMT
Number of subjects: 515
Study 38150260 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium doses of GDMT
Number of subjects: 515
Study 38150260 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of GDMT
Number of subjects: 515
Study 38150260 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher GDMT doses at week 2
Number of subjects: 515
Study 38150310 — intervention group
Group type: COMPARATOR
Intervention: Usual care, face-to-face visits every sixth month
Number of subjects: 240
Study 38150310 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring, monthly digital registration of patient-reported outcomes
Number of subjects: 240
Study 38150310 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated care, self-monitoring, no planned visits during the study period
Number of subjects: 240
Study 38150310 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 240
Study 38150444 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life communication strategies
Number of subjects: 0
Study 38150444 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured in-depth interviews and focus group discussions
Number of subjects: 0
Study 38150444 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic analysis
Number of subjects: 0
Study 38150492 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma donor-derived cell-free DNA (dd-cfDNA) measured by the Prospera test in AMR biopsies.
Number of subjects: 604
Study 38150492 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma dd-cfDNA in AKI biopsies.
Number of subjects: 604
Study 38150492 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma dd-cfDNA in TCMR biopsies.
Number of subjects: 604
Study 38150492 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma dd-cfDNA in biopsies classified as MMDx Normal and NRNI.
Number of subjects: 604
Study 38151173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 150
Study 38151173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 38151258 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial rheoplasty (BR) with the RheOx system
Number of subjects: 21
Study 38151280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) from a lean donor
Number of subjects: 60
Study 38151280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 38151309 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR
Number of subjects: 23562
Study 38151311 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 211
Study 38151311 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 211
Study 38151313 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 11957
Study 38151376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index during hospitalization and at 1, 5, 9, and 13 weeks post-discharge
Number of subjects: 232
Study 38151376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nagi Mobility Scale during hospitalization and at 1, 5, 9, and 13 weeks post-discharge
Number of subjects: 232
Study 38151376 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental Activities of Daily Living during hospitalization and at 1, 5, 9, and 13 weeks post-discharge
Number of subjects: 232
Study 38151376 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Activities of Daily Living during hospitalization and at 1, 5, 9, and 13 weeks post-discharge
Number of subjects: 232
Study 38151376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index score as a predictor of mobility impairment
Number of subjects: 232
Study 38151388 — intervention group
Group type: EXPERIMENTAL
Intervention: epcoritamab monotherapy
Number of subjects: 157
Study 38151502 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentum Distillation-enhanced Composite Transformer Attention (MD-CTA) model
Number of subjects: 395
Study 38151502 — intervention group
Group type: COMPARATOR
Intervention: Convolution Neural Network (CNN)
Number of subjects: 395
Study 38151502 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-CTA model
Number of subjects: 395
Study 38151502 — intervention group
Group type: COMPARATOR
Intervention: CNN
Number of subjects: 395
Study 38151533 — intervention group
Group type: COMPARATOR
Intervention: Higher levels of proteins in M_IT compared to F_NL and F_IT.
Number of subjects: 19
Study 38151533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein to fiber ratio (P/F) in M_IT.
Number of subjects: 19
Study 38151533 — intervention group
Group type: COMPARATOR
Intervention: Plant protein to animal protein (PP/AP) and PP to total proteins ratio in F_NL.
Number of subjects: 19
Study 38151605 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS complex features during the first month of life
Number of subjects: 17450
Study 38151682 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 53
Study 38151682 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 53
Study 38151682 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 53
Study 38151682 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision
Number of subjects: 53
Study 38151766 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma plasma-derived exosomes
Number of subjects: 15
Study 38151766 — intervention group
Group type: EXPERIMENTAL
Intervention: Male trauma plasma-derived exosomes
Number of subjects: 15
Study 38151766 — intervention group
Group type: EXPERIMENTAL
Intervention: Female trauma plasma-derived exosomes
Number of subjects: 15
Study 38151766 — intervention group
Group type: COMPARATOR
Intervention: Elective total hip arthroplasty (THA)
Number of subjects: 15
Study 38151867 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal disability trajectory
Number of subjects: 422
Study 38151867 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild disability trajectory
Number of subjects: 422
Study 38151867 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate disability trajectory
Number of subjects: 422
Study 38151867 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe disability trajectory
Number of subjects: 422
Study 38151867 — intervention group
Group type: EXPERIMENTAL
Intervention: Post COVID-19 condition
Number of subjects: 422
Study 38151867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition
Number of subjects: 422
Study 38152017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutivia
Number of subjects: 151
Study 38152017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutivia + serum creatinine at biopsy
Number of subjects: 151
Study 38152017 — intervention group
Group type: COMPARATOR
Intervention: Serum creatinine at biopsy alone
Number of subjects: 151
Study 38152017 — intervention group
Group type: EXPERIMENTAL
Intervention: Model cut-off of 50 (scale 0-100)
Number of subjects: 151
Study 38152395 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab and nivolumab
Number of subjects: 58
Study 38152404 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal treatment
Number of subjects: 419
Study 38152412 — intervention group
Group type: EXPERIMENTAL
Intervention: ixoberogene soroparvovec (ixo-vec) gene therapy
Number of subjects: 30
Study 38152462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DXM) 400 mg/70 kg
Number of subjects: 20
Study 38152462 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (10, 20, 30 mg/70 kg)
Number of subjects: 20
Study 38152462 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 20
Study 38152640 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% neutral buffered formalin (NBF) fixation for 1-30 days
Number of subjects: 80
Study 38152640 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% neutral buffered formalin (NBF) fixation for 30-60 days
Number of subjects: 80
Study 38152640 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% neutral buffered formalin (NBF) fixation for 60-90 days
Number of subjects: 80
Study 38152640 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% neutral buffered formalin (NBF) fixation for 90+ days (up to 2 years)
Number of subjects: 80
Study 38152640 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% neutral buffered formalin (NBF) fixation for all groups
Number of subjects: 80
Study 38152664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal urinary antigen tests
Number of subjects: 518
Study 38152664 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral and bacterial analysis from nasopharyngeal swabs
Number of subjects: 518